Search filters

List of works by Dharminder Chauhan

2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells

scientific article published in September 2002

A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells

scientific article

A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells

scientific article published on September 2005

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

scientific article

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

scientific article

A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance

scientific article

A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells ⬇️

scientific article published on March 31, 2011

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells

scientific article

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

scientific article published in August 2002

Antimyeloma activity of heat shock protein-90 inhibition.

scientific article published on 18 October 2005

Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma

scientific article published on December 2003

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo

scientific article

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

scientific article published in June 2002

Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications

scientific article published on 06 March 2009

Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines

scientific article published on November 2003

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

scientific article

Bortezomib in the management of multiple myeloma ⬇️

scientific article published on September 8, 2009

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells

scientific article published on 12 May 2009

Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib

scientific article

Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells

scientific article published on 2 December 2015

Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma

scientific article

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma

scientific article

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

scientific article published on 19 August 2004

Cytokines modulate telomerase activity in a human multiple myeloma cell line.

scientific article published on July 2002

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib

scientific article published on April 2009

Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells

scientific article published on 16 December 2015

Ex vivo induction of multiple myeloma–specific cytotoxic T lymphocytes ⬇️

scientific article published on April 24, 2003

FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma

scientific article published on March 2006

FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance

scientific article published in August 2005

Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

scientific article

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment

scientific article published on 26 November 2003

Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis

scientific article

Identification and validation of novel therapeutic targets for multiple myeloma

scientific article

Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays

scientific article

Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays

scientific article published on February 2002

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

scientific article

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

scientific article published on 25 September 2003

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

scientific article published on December 2005

In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells

scientific article

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells

scientific article

In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.

scientific article published on 14 September 2009

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells

scientific article published on September 2007

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.

scientific article published on September 2003

Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib

scientific article published on 24 November 2009

Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity

scientific article published on 03 July 2013

Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells

scientific article

MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo

scientific article published on 01 October 2006

Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings ⬇️

scientific article published on 07 July 2011

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.

scientific article published on 9 May 2016

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

scientific article published on April 2004

Melflufen - a peptidase-potentiated alkylating agent in clinical trials

scientific article published on 8 June 2017

Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study

scientific article published on 23 March 2020

Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.

scientific article published on April 2005

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

scientific article published on 26 September 2002

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

scientific article

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

scientific article published on 16 January 2003

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

scientific article

NF-kappa B as a therapeutic target in multiple myeloma

scientific article

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

scientific article

New proteasome inhibitors in myeloma

scientific article published on December 2012

Novel biologically based therapies for multiple myeloma

scientific article

Novel targeted agents in the treatment of multiple myeloma

scientific article published on 05 August 2014

Novel therapies in the treatment of multiple myeloma

scientific article published on October 2009

Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein

scientific article published on 01 January 2003

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

scientific article published on 17 January 2006

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1

scientific article

Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells ⬇️

scientific article published on September 26, 2011

Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.

scientific article published on December 2004

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

scientific article published in November 2003

Proteasome inhibitor therapy in multiple myeloma

scientific article

Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells

scientific article published on 01 May 2003

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment

scientific article published on July 2006

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

scientific article

Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide

scientific article

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis

scientific article

Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma

scientific article published on 01 October 2007

Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.

scientific article

Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells

scientific article

Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)

scientific article published on 10 October 2006

Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu

scientific article published on 5 September 2002

Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma

scientific article published on April 2007

The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.

scientific article

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance

scientific article published on 11 December 2003

The malignant clone and the bone-marrow environment

scientific article published on December 2007

The power of proteasome inhibition in multiple myeloma

scientific article published on 14 November 2018

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

scientific article published on 7 November 2002

The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies

scientific article published on December 2007

The treatment of relapsed and refractory multiple myeloma

scientific article published on January 2007

Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment

scientific article

VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis

scientific article published on 24 June 2004

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

scientific article

p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma

scientific article published on 12 January 2017

Paulina is supported by:

About Paulina

Help